Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announced that the number of shares and votes in the Company has changed due to the recently completed Rights Issue (for further information, see the Company’s press release on April 4, 2025).
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”), (Nasdaq First North Growth Market: GUARD) announced on 10 March 2025 that the Board of Directors had resolved, by virtue of the authorization granted by the extraordinary general meeting held on 6 March 2025, on a rights issue of shares of approximately SEK 150 million (the “Rights Issue”). The subscription period ended on 3 April 2025. Guard Therapeutics hereby announces that the final result of the Rights Issue shows that 6,852,654 shares, corresponding to approximately 69.7 percent of the Rights Issue, were subscribed for with and without exercise of subscription rights. Accordingly, 1,020,099 shares, corresponding to approximately 10.4 percent of the Rights Issue, will be allotted to the guarantors, whereby the Rights Issue is subscribed to in aggregate approximately 80.0 percent. Guard Therapeutics will receive proceeds amounting to approximately SEK 120 million before deduction of costs attributable to the Rights Issue.
Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled in the Phase 2b POINTER study, which is evaluating the drug candidate RMC-035 as a kidney-protective treatment for patients undergoing open-heart surgery. This patient cohort serves as the basis for the study’s next major milestone – the second of two independent, company-blinded safety reviews. The outcome of this analysis is expected in the second quarter of 2025.
Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") (Nasdaq First North Growth Market: GUARD) publishes information document relating to the rights issue of shares of approximately SEK 150.0 million before deduction of issue costs, which was resolved by the Board of Directors on 10 March 2025, by virtue of the authorization granted by the extraordinary general meeting held on 6 March 2025 (the “Rights Issue”). Due to the Rights Issue, the Board of Directors has decided to postpone the annual general meeting to 15 May 2025.
Guard Therapeutics announced today that an independent Data Safety Monitoring Committee (DSMC) has completed its first planned review of safety data and has recommended that the Phase 2b clinical study POINTER continue as planned. The committee reviewed safety data from 67 patients, corresponding to more than one-third of the planned number of patients in the study, which evaluates the drug candidate RMC-035 as a kidney protective treatment in open-heart surgery.
Guard Therapeutics today announced the formation of a new Scientific Advisory Committee comprising seven globally recognized experts in nephrology and drug development. The committee will play a pivotal role in advising on the company’s late-phase development strategy and the design of the upcoming Phase 3 trial for RMC-035, a kidney protective therapy intended for use in open-heart surgery.
Guard Therapeutics today announced that it has reached the important milestone of enrolling 25% of its target in the phase 2b POINTER study. This trial is evaluating the kidney-protective effects of the investigational drug RMC-035 in patients undergoing open-heart surgery. The next major milestone will be the result of the first of two independent, blinded safety analyses, expected in the first quarter of 2025.
Guard Therapeutics International AB (publ) today announced that a Nomination Committee has been appointed in accordance with previous AGM resolutions.